Article

The use of homologous recombination deficiency (HRD) scores in predicting the prognosis of ovarian cancer

2023-06-16

Abstract excerpt

<h4>Objective: </h4> Predicting the early recurrence rate is important in improving the treatment and prognosis of ovarian cancer (OC). A homologous recombination deficiency (HRD) score serves as a prognostic factor in OC. Whether the HRD score can be used as a new marker for OC prognosis must be further explored. <h4>Methods: </h4>: 69 patients with OC were enrolled in the study. We performed retrospective HRD ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5cf5d169-fec0-5db1-a19d-be107ca2f121
DOI: 10.21203/rs.3.rs-3059241/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The use of homologous recombination deficiency (HRD) scores in predicting the prognosis of ovarian cancerDOI 10.21203/rs.3.rs-3059241/v1Read

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.Semantic proximity Read

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug responseSemantic proximity Read

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025Semantic proximity Read

The Impact of Homologous Recombination Deficiency on First-line Adjuvant Chemotherapy and First-line PARPi Maintenance Therapy in Chinese Patients with Epithelial Ovarian CancerSemantic proximity Read

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 StudySemantic proximity Read

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and managementSemantic proximity Read

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid TumorsSemantic proximity Read

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinomaSemantic proximity Read

Benchmarking homologous recombination deficiency algorithms for prediction of clinical outcome in ovarian cancerSemantic proximity Read

The clinical pathological characteristics and prognostic Relevance of Homologous Recombination Repair Gene Mutations in Ovarian Cancer Patients：A Retrospective Cohort StudySemantic proximity Read

Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancerSemantic proximity Read